,25 Clinical trials with trametinib in KRAS-mutant NSCLC patients, alone or in combination with chemotherapy, show that single agent MEK inhibitors achieve no improvement compared with chemotherapy and that toxicity limits their clinical use in combination.19 This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.